Cameroon vs Russian Federation: Average cost of multi drug-resistant tuberculosis treatment
Cameroon
2,825 constant 2022 US$
in 2024
Russian Federation
2,751 constant 2022 US$
in 2024
Cameroon rank
17th
Russian Federation rank
18th
Average cost of multi drug-resistant tuberculosis treatment over time
- Cameroon
- Russian Federation
How they compare
Cameroon currently reports 2,825 constant 2022 US$ against 2,751 constant 2022 US$ in Russian Federation, a difference of 74 constant 2022 US$.
The two have swapped places 1 time across 7 shared years of data; in 2017 it was Russian Federation ahead.
Cameroon ranks 17th and Russian Federation ranks 18th of 92 countries.
Russian Federation has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Cameroon | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 867.67 constant 2022 US$ | 2,647 constant 2022 US$ | 1,779 constant 2022 US$ | Russian Federation |
| 2020s | 1,010 constant 2022 US$ | 2,819 constant 2022 US$ | 1,809 constant 2022 US$ | Russian Federation |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Cameroon or Russian Federation?
- Cameroon, at 2,825 constant 2022 US$ against 2,751 constant 2022 US$ in Russian Federation as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Cameroon and Russian Federation?
- 74 constant 2022 US$, with Cameroon ahead.
- How many years of comparable data are there for Cameroon and Russian Federation?
- 7 years are reported by both, from 2017 to 2024.
- How do Cameroon and Russian Federation rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Cameroon ranks 17th and Russian Federation ranks 18th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.